| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
PepGen Inc., a Delaware corporation (the “Company”), confirms its agreement with Leerink Partners LLC (“Leerink Partners”), Stifel, Nicolaus & Company, Incorporated (“Stifel”), Guggenheim Securities, LLC (“Guggenheim Securities”) and eac... |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Positive FREEDOM2-DM1 10 mg/kg cohort results demonstrated highest reported splicing correction and improvements across multiple functional measures – |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
– DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg – |
| 22 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) of PepGen Inc. (the “Company”) was held on June 18, 2026. The proposals set forth below were submitted to the stockholders at the 2026 Annual Meeting, with each such pro... |
| 21 May 2026 |
8-K: Regulation FD Disclosure
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticip... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
– FREEDOM2-DM1 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data, with the totality of results supporting the potential of the ongoing 10 mg/kg dose cohort – |
| 30 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data |
| 04 Mar 2026 |
8-K: Regulation FD Disclosure
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticip... |
| 04 Mar 2026 |
8-K: Results of Operations and Financial Condition; Other Events
– Patient dosing in the FREEDOM2 10 mg/kg cohort is proceeding in Canada and the UK, with data expected in 2H 2026 – |
| 08 Dec 2025 |
8-K: Other Events
BOSTON — December 8, 2025-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurologica... |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
– FREEDOM-DM1 15 mg/kg cohort demonstrated the highest mean splicing correction reported to date in DM1 patients – |
| 07 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On November 4, 2025, the Board of Directors (the “Board”) of PepGen Inc. (the “Company”) approved an option repricing (the “Repricing”), effective as of November 4, 2025 (the “Effective Date”). The Repricing was undertaken in accordance ... |
| 01 Oct 2025 |
8-K: Regulation FD Disclosure
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticip... |
| 26 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
PepGen Inc., a Delaware corporation (the “Company”), confirms its agreement with Leerink Partners LLC (“Leerink Partners”), Stifel, Nicolaus & Company, Incorporated (“Stifel”) and each of the other Underwriters named in Schedule A hereto... |
| 24 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
– 53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN- |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
– Last patient dosed in 15 mg/kg cohort of FREEDOM-DM1; on track to report topline data from study in early Q4 2025 – |
| 06 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
The 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) of PepGen Inc. (the “Company”) was held on June 4, 2025. The proposals set forth below were submitted to the stockholders at the 2025 Annual Meeting, with each such prop... |
| 28 May 2025 |
8-K: Regulation FD Disclosure; Other Events
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticip... |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
– Reported positive DM1 patient data with mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – |
| 31 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
BOSTON — March 31, 2025-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological ... |
Loading...